A Phase 1/2 interventional study of BMS-908662 and BMS-908662 in Colorectal Cancer, sponsored by Bristol-Myers Squibb. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-27.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 164th largest by enrollment of the 185 interventional ones that give a count, is one of 12 that started in 2010, is one of 20 in phase 1/2, and was the 78th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Verastem, Inc. · Sites in United States, Australia
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 131 · Phase 3 33 · Phase 4 4
First in 1999; this study’s year is marked. 12 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 185 interventional studies. Of the 108 that completed or were terminated, 29 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 187 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
29 studies in Colorectal Neoplasms by Bristol-Myers Squibb: 4 open now, 9 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 25th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2010, is one of 10 in phase 1/2, and was the 8th registered.
Bristol-Myers Squibb’s Colorectal Neoplasms studies by the year they started, since 2002.
6 of the studies testing cetuximab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06226857Phase 3City Clinical Oncology Hospital No 1Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07659795Verastem, Inc.A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with cetuximab; and then to evaluate the tumor response to BMS-908662 when administered alone or in combination with cetuximab
Phase 1: Single Arm Study
Phase 2: Randomized Controlled, Parallel
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1
Drug: BMS-908662
Phase 1
Drug: Cetuximab
Phase 2
Drug: BMS-908662
Phase 2
Drug: BMS-908662 · Drug: Cetuximab
Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
Capsules, Oral, (TBD) mg, Q 12 h, Continuously
Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
Toxicity will be evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3
Time frame: Assessments every 1-2 weeks while receiving study drug
Efficacy as determined by estimates of objective response rates and response duration
Time frame: Efficacy measured at least every 8 weeks while receiving study drug
Pharmacodynamics (PD) will be assessed by evaluating markers of RAS/RAF pathway activity
Time frame: PD assessed during the first 4 weeks on study
Pharmacokinetics (PK) for BMS-908662 as determined by minimum observed concentrations [Cmin].
Time frame: PK measured during first 4 weeks on study
Pharmacokinetics (PK) for BMS-908662 as determined by maximum observed concentrations [Cmax].
Time frame: PK measured during first 4 weeks on study
Pharmacokinetics (PK) for BMS-908662 as determined by time of maximum observed concentration [Tmax].
Time frame: PK measured during first 4 weeks on study
Pharmacokinetics (PK) for BMS-908662 as determined by area under the concentration-curve for one dosing interval [AUC(TAU)].
Time frame: PK measured during first 4 weeks on study
Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].
Time frame: PK measured during first 4 weeks on study
The record gives a start of Jul 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BMS-908662 · Cetuximab